Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Haleon plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Haleon plc's regulatory disclosures and financial reporting.
Haleon has reported a significant share buyback transaction as part of its program announced on March 28, 2025. On June 19, 2025, the company purchased 1,011,111 ordinary shares for cancellation at prices ranging from 382.80p to 384.90p per share, with a volume-weighted average price of 383.82p.
Following this transaction, Haleon's registered share capital consists of 8,992,573,595 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,988,493,390, a figure relevant for shareholders' disclosure requirements under FCA rules.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
On 19 June 2025, Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting activity under the share buyback programme launched on 28 March 2025. On 18 June 2025 the company repurchased 1,009,204 ordinary shares of £0.01 each for cancellation.
Key transaction metrics
- Shares purchased: 1,009,204
- Price range: 382.90 p – 386.70 p
- Volume-weighted average price: 384.87 p
- Purpose: Cancellation under authorised Buyback Programme
Post-settlement, registered share capital totals 8,993,584,706 ordinary shares, of which 4,080,205 are held in treasury. The resulting number of ordinary shares with voting rights is 8,989,504,501. Investors should apply this updated figure when assessing FCA disclosure thresholds.
A trade-by-trade schedule, published to comply with Article 5 of the UK Market Abuse Regulation, is available via the London Stock Exchange link provided. The filing reiterates that the announcement is not an offer to sell or solicit securities and supplies contact details for investor and media enquiries.